Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different structures and mechanisms of action. MDR has been shown to be associated with overexpression of ATP-binding cassette (ABC) transporters. Here, we report that telatinib, a small molecule tyrosine kinase inhibitor, enhances the anticancer activity of ABCG2 substrate anticancer drugs by inhibiting ABCG2 efflux transporter activity. Co-incubation of ABCG2-overexpressing drug resistant cell lines with telatinib and ABCG2 substrate anticancer drugs significantly reduced cellular viability, whereas telatinib alone did not significantly affect drug sensitive and drug resistant cell lines. Telatinib at 1 μM did not significantly alter the expression of ABCG2 in ABCG2-overexpressing cell lines. Telatinib at 1 μM significantly enhanced the intracellular accumulation of [3H]-mitoxantrone (MX) in ABCG2-overexpressing cell lines. In addition, telatinib at 1 μM significantly reduced the rate of [3H]-MX efflux from ABCG2-overexpressing cells. Furthermore, telatinib significantly inhibited ABCG2-mediated transport of [3H]-E217βG in ABCG2 overexpressing membrane vesicles. Telatinib stimulated the ATPase activity of ABCG2 in a concentration-dependent manner, indicating that telatinib might be a substrate of ABCG2. Binding interactions of telatinib were found to be in transmembrane region of homology modeled human ABCG2. In addition, telatinib (15 mg/kg) with doxorubicin (1.8 mg/kg) significantly decreased the growth rate and tumor size of ABCG2 overexpressing tumors in a xenograft nude mouse model. These results, provided that they can be translated to humans, suggesting that telatinib, in combination with specific ABCG2 substrate drugs may be useful in treating tumors that overexpress ABCG2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 2×
“These ABC transporters reduce the amount of anticancer drug inside cancer cells by eliminating substrate anticancer drugs against the concentration gradient by ATP-dependent active efflux [1,3,5,6].”
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“ABCG2 is also reported as a molecular marker for side-population (SP) characterization [18].”
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Deeley, R. G., Westlake, C., & Cole, S. P. C. (2006) · Physiological Reviews · doi:10.1152/physrev.00035.2005 · Cited by 761 · cited 2×
“Multidrug resistance (MDR) is a phenomenon of simultaneous resistance exhibited by cancer cells to anticancer drugs with different structures and mechanisms of action [1,2].”
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · cited 1×
“Several reversal agents have been reported as inhibitor and/or substrate of ABC transporters [26,27,43,44].”
Self-citation
Cited by
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationChen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Self-citationKrchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
“ABCG2 (BRCP) brigatinib [9]; gefitinib [58] axitinib [34]; cabozantinib [15]; canertinib * [31]; ceritinib [38]; erlotinib [34]; icotinib * [59]; linsitinib * [13]; masitinib * [60]; osimertinib [40]; quizartinib * [61]; regorafenib [34]; sorafenib [24]; sunitinib [21]; tandutinib * [15]; vandetanib [42]; vatalanib *…”
BackgroundZhang, H., Wang, Y.-J., Zhang, Y.-K., Wang, D.-S., Kathawala, R. J., Patel, A., Talele, T. T., Chen, Z.-S., & Fu, L.-W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.008 · Cited by 34
“The cells were collected and lysed for the detection of radioactivity as described previously [33,35].”
MethodSelf-citation
Metadata
- Authors
- Sodani, K., Patel, A., Anreddy, N., Singh, S., Yang, D.-H., Kathawala, R. J., Kumar, P., Talele, T. T., & Chen, Z.-S.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 89
- Issue
- 1
- Pages
- 52-61
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1970373339
- Cited by
- 47
- References
- 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. https://app.cochat.ai/papers/10.1016/j.bcp.2014.02.012
- The paper
- Sodani, K., Patel, A., Anreddy, N., Singh, S., Yang, D.-H., Kathawala, R. J., Kumar, P., Talele, T. T., & Chen, Z.-S. (2014). Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2014.02.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.